Bladder

Article

Article Types

Year

—

Volume

Issue

Pages

—

Bladder

Editors-in-Chief: Hohenfellner Markus , Zhang Xu

Indexed in: PubMed Central (PMC), Chemical Abstracts Service, ASCI, EBSCO, Europub, Google Scholar, CrossRef, OCLC, SHERPA/RoMEO.

The Bladder is an international, open-access journal committed to publishing top-quality peer-reviewed articles describing basic laboratory, translational, and clinical investigations in the broad fields of bladder biology and diseases, including benign and malignant conditions.

Gold Open Access

Charge APCs

Double-Blind Peer Review

Archived in Portico

Editorial Board

learn

Richard E. Hautmann

Department of Urology, Ulm University, Ulm, Germany

Interests: Bladder cancer; Radical cystectomy; Urinary diversion; Ileal neobladder; Oxalate; Renal handling of oxalate; Stone metabolism; Pathophysiology of stone formation

Markus Hohenfellner

Department of Urology, University of Heidelberg Medical Center, Heidelberg, Germany

Interests: Urology and oncology surgery; Minimally invasive urology; Reconstructive urology

Xu Zhang

Department of Urology, Chinese PLA General Hospital, Beijing, China

Interests: Urology; Urology laparoscopic surgery

Weimin Ci

Department of Urology, The Third Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

Interests: Cancer epigenetics; Urine liquid biopsy; Precision medicine of genitourinary cancers

Hongzhao Li

Department of Urology, The Third Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

Interests: Urology; Kidney cancer

Benyi Li

Department of Urology, The University of Kansas Medical Center, Kansas City, USA

Interests: Urology; Prostate cancer; Novel and clinically beneficial therapeutics

917

Authors

Editorial Board

156

Articles

574437

Article Views

4415

Article Downloads

168

Reviewer Board

Academic Talks

Frontier Lens

Global Insights into Bladder Health

Articles

Latest Articles Most Viewed Most Downloaded

A prospective, multicenter, single-arm, phase II, exploratory clinical trial protocol for the evaluation of efficacy and safety of Distitamab Vedotin plus tislelizumab combined with re-TURBT for the treatment of high-HER2-expressing (2+/3+) non-muscle invasive bladder cancer at high/very high-risk

https://doi.org/10.14440/bladder.0403

Abstract Download PDF(983.97KB) XML

Testing the external validity of the standard vs. extended lymphadenectomy for muscle invasive bladder cancer trial in a north American cohort

https://doi.org/10.14440/bladder.026040009

Abstract Download PDF(1.32MB) XML

Current evidence on the role of urinary microbiome in bladder cancer: A narrative review

https://doi.org/10.14440/bladder.0464

Abstract Download PDF(563.51KB) XML

Innate immune axis in non–muscle-invasive bladder cancer: Neutrophils, macrophages, natural killer cells, and dendritic cells in prognosis and BCG response

https://doi.org/10.14440/bladder.0438

Abstract Download PDF(1013.34KB) XML

Archives

learn

Issue 2

Jun 26, 2026